Status:

COMPLETED

A Study of Fibrocaps in Liver Surgery in the Netherlands

Lead Sponsor:

Mallinckrodt

Conditions:

Postoperative Hemorrhage

Eligibility:

All Genders

18+ years

Phase:

PHASE2

Brief Summary

A multi-center, prospective, randomized, single-blind, controlled, comparative efficacy and safety trial in subjects undergoing open liver resection surgery. The study will enroll 42 eligible subjects...

Detailed Description

This will be a multi-center, prospective, randomized, single-blind, controlled, comparative efficacy and safety trial in 60 subjects undergoing hepatic resection. Subjects will be randomized in a 2:1 ...

Eligibility Criteria

Inclusion

  • Male or female ≥ 18 years of age
  • Subjects who are able and willing to provide written and signed informed consent
  • Willing to use a medically accepted form of contraception from the time of consent to completion of all follow-up study visits
  • Has a life expectancy of at least one year
  • Presence of mild or moderate bleeding/oozing and control by conventional surgical techniques including but not limited to suture, ligature, and cautery is ineffective or impractical

Exclusion

  • Pregnant or lactating women
  • Has a known intolerance to blood products or to Fibrocaps components
  • Unwilling to receive human blood products
  • Subject has a known allergy to porcine gelatin
  • Has a mental or physical condition that would, in the opinion of the Investigator, place the subject at an unacceptable risk or render the subject unable to meet the requirements of the protocol
  • Currently participating or has participated in another clinical study involving another investigational agent within 4 weeks of the planned date of surgery, or is planning participation in another clinical trial during the 4 weeks after surgery
  • Has any clinically-significant coagulation disorder that may interfere with the assessment of efficacy or pose a safety risk to the subject according to the Investigator
  • Platelets(PLT) \< 100 x109 PLT/L during screening
  • Activated Partial Thromboplastin Time (aPTT) \> 100 seconds during screening
  • International Normalized Ratio (INR) \> 2.5 during screening

Key Trial Info

Start Date :

December 1 2010

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

October 1 2011

Estimated Enrollment :

56 Patients enrolled

Trial Details

Trial ID

NCT01256190

Start Date

December 1 2010

End Date

October 1 2011

Last Update

August 22 2016

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

University Medical Center Groningen

Groningen, Netherlands